21
Participants
Start Date
July 28, 2022
Primary Completion Date
September 3, 2024
Study Completion Date
October 17, 2024
Damoctocog alfa-pegol is a recombinant B-domain deleted human coagulation FVIII variant site specifically conjugated with a 60 kDa, branched (30 kDa each) polyethylene glycol (PEG).
"Dosage Levels:~* 40 IU/kg/dose two times per week~* 50 IU/kg/dose every 5 days~* 60 IU/kg/dose, Less frequent dosing (e.g. every 7 days), the total recommended maximum dose/infusion is 6000 IU."
Aflac Cancer and Blood Disorders Center, Atlanta
Augusta University Medical Center, Augusta
University of Miami Hospital, Miami
Michigan State University, East Lansing
The University of Iowa - Div of Sponsored Programs, Iowa City
University of Minnesota Medical Center, Minneapolis
Rush University Medical Center, Chicago
Gulf States Hemophilia & Thrombophilia Center-UT Physicians, Houston
Orthopaedic Institute for Children, Los Angeles
Dr. Akshat Jain - Loma Linda University Medical Center, Loma Linda
Loma Linda Children's Hospital, San Bernardino
"University of Colorado , Renal Research Office"
Rutgers Robert Wood Johnson Medical School, New Brunswick
Lead Sponsor
Bayer
INDUSTRY